Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Understand portfolio volatility for bonds versus index funds in retirement and how it affects withdrawal strategies and peace of mind.
23,614 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
NVIDIA’s shares hover near $198 as investors weigh whether the AI leader’s growth justifies a premium. The stock now ...
New York Fed researchers find a widening gap in how households respond to rising gas prices after the Iran-related sh...
Nice stock plummeted today after a mixed earnings release, signaling a need to look beyond a single headline. This gu...
Argus boosts Exxon Mobil's target to $169, signaling confidence in higher 2026 output from Permian and Guyana and a r...
A hypothetical $1,000 XRP bet on election night would have endured wild swings and sharp turns. Here’s the latest rea...
Jet fuel has surged 100% since a regional conflict flared, nudging travelers toward domestic getaways. Two Mega-Cap C...
Is UPS stock a long-term winner? This guide breaks down the turnaround story, real numbers, and a clear plan for eval...
A SpaceX IPO could reshape tech investing, but it won’t happen in a vacuum. This guide explains why Amazon’s space an...
As Nvidia prepares to report earnings in May, investors weigh AI momentum against valuation. This practical guide exp...
The updated senate banking committee rolled out a draft bill to regulate stablecoin rewards and DeFi protocols, signa...
Tesla stock slides roughly 5% intraday as Elon Musk travels to China amid reports of robotaxi glitches and battery pr...